GMI, an Immunomodulatory Peptide from *Ganoderma microsporum*, Restraints Periprosthetic Joint Infections via Modulating the Functions of Myeloid-Derived Suppressor Cells and Effector T Cells

Kuo-Ti Peng 1,2,*, Jiun-Liang Chen 1, Liang-Tseng Kuo 1,2, Wei-An Yu 1, Wei-Hsiu Hsu 1,2, Chiang-Wen Lee 3,4,5, Pey-Jium Chang 6,7, and Tsung-Yu Huang 2,8,9,*

1 Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Puzi 61363, Taiwan; yq0139@cgmh.org.tw (J.-L.C.); light71829@gmail.com (L.-T.K.); b9002065@cgmh.org.tw (P.-A.Y.); 7572@cgmh.org.tw (W.-H.H.)
2 College of Medicine, Chang Gung University, Taoyuan 33303, Taiwan
3 Division of Basic Medical Sciences and Recurrent Diseases, Health Promotion Research Center, Department of Nursing, Chang Gung University of Science and Technology, Puzi 61363, Taiwan; cwlee@mail.cgust.edu.tw
4 Research Center for Industry of Human Ecology, Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan
5 Department of Rehabilitation, Chang Gung Memorial Hospital, Puzi 61363, Taiwan
6 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang-Gung University, Taoyuan 33302, Taiwan; peyjiume@mail.cgu.edu.tw
7 Department of Nephrology, Chang-Gung Memorial Hospital, Chiayi 61363, Taiwan
8 Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan
9 Department of Nursing, Chiayi Campus, Chang Gung University of Science and Technology, Chiayi 61363, Taiwan
* Correspondence: mr3497@cgmh.org.tw (K.-T.P.); r12045@cgmh.org.tw (T.-Y.H.); Tel.: +886-(536)-21000 (ext. 2004) (T.-Y.H.)

Abstract: Periprosthetic joint infections (PJIs) caused by *Staphylococcus aureus* infection are difficult to treat due to antibiotic resistance. It is known that the biofilms from methicillin-resistant *S. aureus* (MRSA) promote expansion of myeloid-derived suppressor cells (MDSCs) to suppress T-cell proliferation and benefit bacterial infections. This study finds that GMI, a fungal immunomodulatory peptide isolated from *Ganoderma microsporum*, suppresses MDSC expansion and IL-6 expression. Similar beneficial effects of GMI on the suppression of MDSC expansion and IL-6 expression are also observed in the whole blood and reduces the accumulation of MDSCs in the infected bone region in a mouse PJI infection model. This study shows that GMI is potentially useful for treating *S. aureus*-induced PJIs.

Keywords: periprosthetic joint infections; GMI; T cells; myeloid-derived suppressor cells

1. Introduction

*Staphylococcus aureus* is a Gram-positive bacterium causing periprosthetic joint infections (PJIs) [1,2]. In primary total joint arthroplasties, the PJI incidence is 1–2%, although 2–6% was observed in revision joint arthroplasties [3]. Although many strategies have been developed to improve PJI treatments [4,5], including debridement with prosthesis retention, one-stage or two-stage reimplantation, and antibiotic therapy, high treatment failure rates of 10-30% during follow-ups [1,6–8] cause a huge financial burden on patients [9,10]. PJI caused by *S. aureus* infection is particularly difficult to treat as this pathogen produces biofilms and is highly resistant to many antibiotics [11–16]. Furthermore, *S. aureus* often...
contaminates surgical instruments and implants, making the treatment of PJI challenging [17,18]. Therefore, this study seeks a treatment method that improves antibiotic therapy of PJIs caused by MRSA infection.

Myeloid-derived suppressor cells (MDSCs), an innate immune cell subset, are known to decrease immune-mediated pathology of the hosts to prevent the collateral damage caused by host immune responses [19]. However, the decreased immunity often provides advantages to bacterial infection [19]. For instance, *S. aureus* promotes the expansion of MDSCs from bone marrow cells (BMCs) to suppress T-cell proliferation, resulting in decreased host immunity [20]. Therefore, compounds that prevent or reverse the expansion of MDSCs may be beneficial to the treatments of PJI.

Many natural compounds have been reported to have immunomodulatory and overall health-benefiting effects to people. These compounds are considered safer and less toxic than the synthetic drugs [21,22]. Fungal immunomodulatory proteins (FIPs) are a group of peptides, which are known to modulate immunity [23,24]. So far, 38 types of FIPs have been identified, which are classified into five subgroups [24]. It is well known that FIPs have anti-inflammatory, anti-cancer, and anti-allergic activities. FIPs also inhibit replication of respiratory syncytial virus and microglia [23–26]. *Ganoderma* spp., also called Lingzhi or Reishi, is a popular chemoprevention mushroom. GMI (GenBank AGU04723.1), the FIP from *Ganoderma microsporum*, is a 111-amino acid peptide and one of the active components in the mushroom. The gene encoding GMI, *Pichia pastoris*, has been cloned and can be produced by yeast and is widely used in biochemical research and biotech industries [24,27]. The recombinant GMI was demonstrated to regulate cytokine expression, inhibit lung cancer cells [28–31], and have anti-inflammatory and neuroprotective activities [26]. This study finds that both in vitro and in an *S. aureus*-induced mouse PJI model, GMI promotes T cell proliferation via suppression of MDSC expansion, increases cytokine expression, and reduces ROS, showing that GMI is an attractive candidate for PJI treatment.

2. Materials and Methods

2.1. Animals

Male C57BL/6j mice that were 8–12 weeks old with weights from 22–25 g were purchased from National Laboratory Animal Center (Taiwan). The mice were acclimated to a room with controlled temperature (25 °C) and humidity (50 ± 10%) with a 12-h day-night cycle. The studies were approved by the Institutional Animal Care and Use Committee of the Chang Gung Memorial Hospital (IACUC permit number: 2019122309) and were performed in accordance with the Animal Protection Law by the Council of Agriculture, Executive Yuan (Taiwan) and the guidelines of National Research Council (USA) for the care and use of laboratory animals.

2.2. GMI, *S. aureus* and Biofilm Preparation

GMI is a fungal immunomodulatory protein from *Ganoderma microsporum* (NCBI protein ID AGU04723.1) and was provided by MycoMagic Biotechnology Co, Ltd. (Taipei, Taiwan).

*S. aureus* ATCC43300, a MRSA strain, was purchased from the Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan). The bacteria were cultured in brain heart infusion (BHI) media (Bacto, Sydney, Australia). After culturing for 4 days, *S. aureus* biofilms were then prepared by autoclaving and centrifugation according to a method reported elsewhere [20]. The biofilms were suspended in RPMI 1640 medium; the number of proteins in the biofilms was quantified using a BCA protein assay kit (Pierce) and was adjusted to 0.2 mg/mL with RPMI 1640 medium. For experiments using live bacteria, *S. aureus* was harvested by centrifugation and enumerated spectrophotometrically by measuring the turbidity at 600 nm (A600) and by viable cell counts.

2.3. Isolating MDSCs from Mouse Bone Marrow by Cell Sorting

Bone marrow cells (BMCs) in mouse femur were collected and treated with anti-CD11b antibody conjugated with FITC and anti-Gr1 antibody conjugated with PE according to
the methods described earlier [20]. MDSCs, which were stained by both antibodies, were sorted with a FACSAria Fusion cell sorter (BD). The purity of the isolated cell population was then verified by flow cytometry.

2.4. Analysis of MDSC Expansion

Transwell plates with 0.4-µm pore size inserts were used to examine how biofilms and GMI influenced MDSC expansion. BMCs were cultured in the lower compartment in RPMI 1640 medium containing 10% fetal calf serum with different concentrations of GMI; S. aureus biofilms (0.2 mg/mL) were added to the inserts. The membrane in the inserts prevented the presence of biofilm debris in the lower compartment to interfere with flow cytometry analysis of BMCs and MDSCs. After culturing for 48 h, cells stained with anti-CD11b-FITC and anti-Gr1-PE antibodies were analyzed using flow cytometry (BD FACSCanto II) to determine the numbers of MDSC proportion. Acquisition of flow cytometry data from the flow cytometer was performed using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). The number of events analyzed was 10,000 per sample. Analysis was performed using FlowJo software (Tree Star, Ashland, OR, USA).

2.5. Analysis of Tc, Th, Treg Cells by Flow Cytometry

After treating BMCs with biofilms for 48 h, MDSCs were isolated by sorting as described above. MDSCs (1 × 10^5 cells) were then treated with GMI, washed with PBS, and cocultured for 48 h with CFSE-labeled spleen T cells (2 × 10^5 cells) that were stimulated by Dynabeads Mouse T-Activator CD3/CD28 (Gibco). The mouse spleen T cells were purified and labeled with CFSE according to a method described elsewhere [20]. Cells were then stained with anti-CD3-PerCP-Cy5.5 (BD Bioscience), anti-CD4-APC-H7 (BD Bioscience), anti-CD8-PE-Cy7 (BD Bioscience), anti-CD25-PE (BD Bioscience), and anti-FoxP3-Alexa Fluor 647 (BD Bioscience) to analyze Tc, Th, and Treg cells by flow cytometry.

2.6. Preparation of Blood Samples for Flow Cytometry Analysis

For determining the effect of GMI on the dynamic changes of the immune cell populations in the peripheral blood of mice, 100 µL blood samples were collected. After lysing red blood cells with ACK Lysing buffer (Thermo Fisher, Waltham, MA USA), leukocytes were suspended in PBS containing 2% FBS. T cells were then analyzed by flow cytometry as described above.

2.7. Analysis of IL-6 and TNF-α in Culture Medium and Plasma

A Cytometric Bead Array (CBA) Mouse Inflammation kit was used to quantify IL-6 and TNF-α in culture medium and blood. After mixing 50 µL cell culture medium or 50 µL blood with the beads, IL-6 and TNF-α captured by the beads were reacted with mouse inflammation PE detection reagent for two hours and analyzed by flow cytometry.

2.8. Measurement of ROS

ROS was measured with 10 µM 2',7'-dichlorofluorescin diacetate (DCFDA) (Sigma-Aldrich, St. Louis, MO, USA) according to a method described by Evgeniy et al. and analyzed by flow cytometry [32].

2.9. GMI Treatment of Mice Infected by S. aureus

Orthopedic implantation was performed in male C57BL/6J mice according to a method described previously [20] and infected with 2 × 10^6 CFU of S. aureus at the intramedullary canal containing the implant. The mice were divided into five groups, including the control group and four different treatment groups (n = 4 for each group), which include (i) the group that received GMI (8 mg/kg) only; (ii) the group that was infected with S. aureus only; (iii–v) the groups that was injected intraperitoneally with different concentrations of GMI (2 and 8 mg/kg) three times a week after the infection with S. aureus for 3 days. Mice that received implants but without S. aureus inoculation served
as the control-operated group. After injection for 2 weeks, the mice were sacrificed, and
the femurs were fixed in 10% formalin.

2.10. Fluorescence Molecular Tomography

The PJI mice were divided into four groups, including the control group and three differ-
ent treatment groups with various concentrations of GMI injection (0, 2, and 8 mg/kg) (n = 4
for each group). After GMI injection for 24 h, DilC18 (7)—labeled MDSCs (5 × 10^6 cells),
were injected via tail vein. The infection sites were observed by fluorescence molecular to-
mography (FMT) at Days 1, 4, and 7. Fluorescence of MDSCs were quantitatively assessed
with TrueQuan software.

2.11. Statistical Analysis

Results were expressed as mean ± standard deviation (SD) and analyzed statistically
by Student’s t-test with GraphPad Prism software (GraphPad, San Diego, CA, USA). A
p-value less than 0.05 was considered significant.

3. Results

3.1. Influence of GMI on S. aureus Biofilm-Mediated MDSC Expansion

In this study, we investigated whether GMI treatments affected MDSC expansion that
was stimulated by S. aureus biofilms [20]. We found that in the absence of GMI, 27% of
BMCs were expanded to MDSCs (Figure 1A). After treating BMCs with S. aureus biofilms, a
1.5-fold increase in MDSC expansion was observed (Figure 1B). The results were consistent
with the results of an earlier study which reported that S. aureus biofilms activates MDSC
proliferation [20]. We also found that although GMI did not seem to promote MDSC expansion
from BMCs that were untreated with S. aureus biofilms (Figure 1A), GMI treatments impacted
the expansion that was stimulated by S. aureus biofilms. We found that GMI at 1 and 2.5
µg reduced the expansion from 1.5-fold to 1.2- and 1.1-fold, respectively (Figure 1B).

3.2. Activation of IL-6 and TNF-α Expression by GMI

S. aureus biofilms are known to stimulate the production of inflammatory cytokines,
including IL-6 and TNF-α [33]. In this study, we found that little IL-6 was released into the
culture medium by MDSCs that were untreated with biofilms and GMI (Figure 1C). When
the cells were treated with 0.5 µg/mL GMI, the amounts of IL-6 increased only a little. How-
ever, if the concentration of GMI increased to 1 and 2.5 µg/mL, the amounts of IL-6
increased to 10 ng/mL and 50 ng/mL, respectively (Figure 1C), showing that GMI activates
the expression of IL-6 from MDSCs untreated with biofilms. We also found that MDSCs that
were treated with biofilms produced 27 ng/mL IL-6, an amount substantially higher than
that produced by MDSCs untreated with biofilms (Figure 1C), verifying our earlier findings
that S. aureus biofilms stimulates IL-6 expression [20]. When biofilm-treated MDSCs were
incubated with 0.5 to 2.5 µg/mL GMI, the amounts of IL-6 increased from 25 to 225 ng/mL
in a dose-dependent manner (Figure 1C), showing that GMI promotes the expression of
IL-6 by the cells treated with biofilms. We also found that MDSCs untreated with biofilms
produced little TNF-α even when the cells were incubated with GMI (Figure 1D). However,
we found that GMI stimulated TNF-α expression by the cells treated with biofilms. The
results showed that the cells untreated with GMI produced 2700 ng/mL TNF-α; the
concentration increased from 2800 to 4800 ng/mL in a dose-dependent manner when the
cells were treated with 0.5 to 2.5 µg/mL GMI (Figure 1D). These results showed that GMI
promotes TNF-α expression by the MDSCs treated with biofilms.

3.3. Reduction in ROS Expression by GMI

MDSCs are known to release ROS to suppress T cell responses [34]. We found that
although GMI did not seem to affect the release of ROS after the cells were treated with 0.5
and 1 µg GMI (Figure 1E), a reduction in ROS expression by 40% from 3000 to 1800 units
DCF fluorescence was observed when compared with the ROS from cells untreated with
GMI (Figure 1E). These results showed that GMI reduces the amounts of ROS produced by the cells that are treated with biofilms.

**Figure 1.** Influence of GMI on MDSC expansion and IL-6, TNF-α, and ROS production. BMCs were treated with *S. aureus* biofilms GMI for 48 h. BMCs were also untreated with the biofilm but treated with GMI for the purpose of comparison. The number of MDSCs, which were CD11b-FITC and Gr1-PE positive, were determined by cell sorting with a cell sorter. The percentage of MDSCs in the whole cell population was presented (A). The number of MDSCs from BMCs treated with biofilms was divided by those untreated with biofilms to show the fold increase in the enhancement of MDSC expansion by biofilms (B). The amounts of IL-6 and TNF-α produced by the cells were determined using a CBA kit followed by flow cytometry. (C,D). Cells were treated with 10 µM DCFDA, cell population with ROS production was determined by flow cytometry (E). The results were analyzed statistically with Student’s *t*-test. *: *p* < 0.05.

### 3.4. Effects of GMI on the Suppression of T Cell Proliferation by MDSCs

MDSCs were prepared using a cell sorter from BMCs that were treated or untreated with biofilms. MDSCs were then treated with GMI for 24 h and then cocultured with CFSE-labeled T cells treated with anti-CD3/CD28 antibodies that were conjugated to magnetic beads for 48 h at a ratio of 1:2 (1 × 10⁵:2 × 10⁵) to test how GMI treatment affected MDSC’s ability to suppress T cell proliferation. We found that in the case of MDSCs from BMCs
that were untreated with biofilms, the number of T cells increased by 30% if GMI was not added to the culture. The number of T cells increased from 30% to 34%, 46%, 61% after 0.5, 1, and 2.5 µg GMI was added, respectively (Figure 2), showing the promotion of T cell proliferation by GMI. GMI also promoted T cell proliferation that was suppressed by MDSCs from BMCs treated with biofilms. In the absence of GMI, an increase of 20% of T cells was observed (Figure 2), however, the percentage increased to 25%, 50%, 61.5% after 0.5, 1, and 2.5 µg GMI was added, showing that GMI inhibits the suppression of T cell proliferation by MDSCs.

![Figure 2](image-url)

**Figure 2.** Influence of GMI on the suppression of T cell proliferation by MDSCs. Freshly isolated mouse BMCs were untreated or treated with 0.2 mg/mL *S. aureus* biofilms for 48 h. MDSCs expanded from BMCs were treated with anti-CD11b antibody conjugated with FITC and anti-Gr1 antibody conjugated with PE. The cells that were bound to both antibodies were separated using a cell sorter. MDSCs were treated with different concentrations of GMI for 24 h and then cocultured with activated CFSE-labeled T cells at a ratio of 0.5:1. The results were analyzed statistically with Student’s *t*-test. *: *p* < 0.05.

We further investigated the specific T cell subtypes that were affected by GMI treatment. We cocultured MDSCs and T cells for 48 h then treated the cells with anti-CD3 antibody conjugate to PerCP-Cy5.5 and anti-CD8 antibody conjugated with PE-Cy7 to label Tc cells. T\(_H\) cells in the T cell population were similarly labeled with anti-CD3 antibody conjugated with PerCP-Cy5 and anti-CD4 antibody conjugated with APC-H7; Treg, anti-CD3 antibody conjugate with PerCP-Cy5.5, anti-CD4 antibody conjugated with APC-H7, anti-CD25 antibody conjugated with PE, and FoxP3 conjugated with Alexa fluor 647. After flow cytometry analysis, we found that few Tc cells proliferated if the cells were untreated with GMI (Figure 3). However, when 0.5 µg GMI was added to the culture, regardless of whether MDSCs were treated or untreated with biofilms, enhancement of Tc cell proliferation became evident (Figure 3). When T cells were cocultured with MDSCs that were untreated with biofilm, 1 µg GMI increased the Tc cells by 27.5% (Figure 3). If Tc cells were cocultured with MDSCs that were treated with biofilms, a 58% increase was observed (Figure 3). GMI at 1 µg seemed to yield the maximum enhancement as 2.5 µg did not further enhance the proliferation. Unlike Tc cells, the proliferation of T\(_H\) cells did not increase much after treatment with GMI. When T cells were cocultured with MDSCs that were untreated with biofilms, the number of T\(_H\) cells increased by 4%; the proliferation increased to only 6% when they were cultured in the medium containing 1 or 2.5 µg/mL GMI (Figure 3). When T cells were incubated with MDSCs that were treated with biofilms, GMI treatment increased proliferation of T\(_H\) cells by 8% (Figure 3). We also found that after coculturing T cells with MDSCs or biofilm-treated MDSCs, Treg cells increased only by 0.5% and 1%, respectively (Figure 3). When the cells were cocultured in the presence
of 0.5 µg GMI, GMI enhanced the proliferation of Treg cells that were cocultured with biofilm-treated MDSCs to 1.5% while the percent of proliferation was unchanged for the Treg cells when the cells were cocultured with MDSCs untreated with biofilm. In the presence of 1 or 2.5 µg GMI, proliferation of Treg increased to about 1%; when the cells were treated with biofilm, the percentages increased to 2 and 3%, respectively (Figure 3). The results showed that among the three subtypes of T cells, GMI preferentially promotes the proliferation of Tc cells that is suppressed by MDSCs.

![Figure 3](image)

**Figure 3.** Activation of T cell proliferation that was suppressed by MDSCs. MDSCs that were treated or untreated with biofilm were incubated with GMI. At 24 h after incubation, the cells were cocultured for 48 h with activated CFSE-labeled T cells at a ratio of 0.5:1, and proliferation of Tc (A), TH (B), and Treg (C) cells were examined and enumerated by flow cytometry. The results were analyzed statistically with Student’s t-test. *: p < 0.05.

3.5. Promotion of T Cell Proliferation by GMI

After demonstrating that GMI promotes T cell proliferation that is suppressed by MDSCs, we further investigated whether GMI directly promoted T cell proliferation in the absence of MDSCs. We found that GMI promoted T cell proliferation in a dose-dependent manner. After adding 0.5, 1, and 2.5 µg GMI, T cell proliferation increased from 1% to 37%, 42%, and 70%, respectively (Figure 4). The results indicated that GMI can either indirectly promote T cell proliferation by reducing MDSCs’ suppression or directly enhance T cell proliferation.

3.6. Effects of GMI on the Production of Cytokines

As it is commonly known that IL-6 promotes proliferation and activation of T cells [35], we further evaluated whether GMI treatment increased IL-6 production. After treating the cells with GMI for 48 h, IL-6 in the culture medium was captured with CBA beads and quantified by flow cytometry. We found that in the absence of GMI, little IL-6 was expressed. However, 6, 8, 9 ng/mL IL-6 were detected in the medium when cells were
treated with 0.5, 1, and 2.5 µg GMI, respectively (Figure 5), showing that GMI promotes the synthesis of IL-6, from T cells.

3.7. Effects of GMI on S. aureus-Induced Mouse PJI Model

This study used an S. aureus induced mouse PJI model [20,36] to evaluate whether GMI is useful for treating PJI. As shown in Figure 6A, the X-ray image showed that the bone had severe permeated pathologic fractal after S. aureus infection. We also observed that treatment with 8 mg/kg GMI reduced osteolytic destructions (Figure 6). We also studied whether GMI-suppressed MDSC expansion and cytokine changes could be observed in the mouse PJI model. S. aureus infection increased MDSCs levels in PBMCs by 21-fold as compared to the control group (Figure 6). We found that MDSC expansion was reduced in GMI treatment groups in a dose-dependent manner; the groups treated with 2 mg/kg and 8 mg/kg GMI decreased the number of MDSCs by 30.7% and 61.9%, respectively (Figure 6B). A similar pattern was obtained for the IL-6 in blood (Figure 6C). S. aureus infection caused a 10.4-fold

![Figure 4](image1.png)

**Figure 4.** Enhancement of T cell proliferation by GMI. T cells were incubated with GMI for 48 h. T cells were then enumerated by flow cytometry. The results were analyzed statistically with Student’s t-test. *: p < 0.05.

![Figure 5](image2.png)

**Figure 5.** Expression of IL-6 by T cells after GMI treatment. T cells were cultured in the presence of GMI for 48 h. IL-6 in the culture medium was assayed by a CBA kit. The results were analyzed statistically with Student’s t-test. *: p < 0.05.
increase in IL-6. The level decreased to 41% and 60.9% after the mice were injected with 2 mg/kg GMI and 8 mg/kg GMI, respectively (Figure 6). The results showed that GMI not only reduces MDSC expansion but also increases expression of IL-6 in mice.

Figure 6. Influence of GMI treatment on S. aureus infection in a mouse PJI model. Mice were divided into five groups (n = 4): (i) control group (ii) GMI (8 mg/kg) only; (iii) infected with S. aureus only; (iv,v) infected with S. aureus and injecting 2 and 8 mg/kg GMI. (A) X-ray images (upper) and histological staining (lower) of femur in mice infected with S. aureus are shown. Black arrow indicates S. aureus infection site and bone destruction; White arrow showed infiltrating mononuclear immune cells. (B) MDSCs in PBMCs were enumerated by flow cytometry. (C) The concentration of IL-6 in GMI-treated mice that were uninfected or infected with S. aureus was determined using a CBA kit. The results were analyzed statistically with Student’s t-test. *: p < 0.05.

It is known that S. aureus promotes local MDSC accumulation in the infected regions [37–40]. To demonstrate how GMI affected the accumulation of MDSC in a prosthesis, we injected mice with 5 × 10⁶ MDSCs that were labeled with a near-IR fluorescent lipophilic cyanine dye DilC18 (7) (‘DiR’) via tail veins, and the infected site was observed by fluorescence molecular tomography (FMT) at Days 1, 4, and 7. We found that introducing GMI decreased the aggregation of MDSC-DiR in the lesion region with a notably decrease during the studying period; MDSCs-DiR signals decreased in group injected with 8 mg/kg
GMI compared to the control PJI group. The signal intensity decreased by 25.2%, 58.1%, and 74.3% at Days 1, 4, and 7, respectively (Figure 7). The results showed that GMI reduces the accumulation of MDSCs at the injection sites.

**Figure 7.** Effects of GMI on the recruitment and accumulation of local MDSCs in the infected regions after *S. aureus* infection. (A) The FMT images obtained on day 1, 4, and 7 after injection. (B) Fluorescence of MDSCs were quantitatively assessed with TrueQuan software. The results were analyzed statistically with Student’s *t*-test. *: *p* < 0.05.

4. Discussion

PJI is a disaster after total joint arthropathy. Treatment of the disease requires surgical intervention and a prolonged antibiotic course. As the failure rate of PJI treatment is
high and the disease is often associated with high morbidity and functional loss, effective
treatment methods are urgently needed [6]. It is commonly known that PJI caused by
*S. aureus* infection is particularly troublesome as *S. aureus* biofilms often persist on
the surface of the implants and are difficult to remove [1]. Additionally, the biofilms are known
to reduce host’s immunity and increase resistance to antibiotics [41], causing the treatment
of *S. aureus* infection extremely difficult. This study finds that GMI is an effective agent
which promotes T cell proliferation that is suppressed by *S. aureus*, making this compound
potentially useful for treating PJI.

MDSC is an innate immune cell subset that decreases immune-mediated pathology of
the hosts to prevent the collateral damage caused by robust host immune responses [19].
However, the decreased immunity often provides advantages to bacterial infection [19]. In
an earlier study, we demonstrated that the biofilms formed by *S. aureus* strains USA300
and Col induce the expansion of MDSC, indicating that *S. aureus* exploits the expansion
of MDSCs and reduced T cell proliferation to benefit their infection. We also demonstrated
that curcumin inhibits MDSC expansion [36], showing that natural compounds may be
useful for treating PJI. As *G. microsporum* has been widely used as a new dietary ingredient
to modulate immunity, this study evaluates a peptide, GMI, isolated from this fungus, to
determine whether this compound has similar effects as curcumin in inhibiting MDSC
expansion. We found that GMI at 2.5 µg substantially reduces the MDSC expansion that
is induced by *S. aureus* biofilms (Figure 1A,B), showing that GMI is potentially useful for
treatment PJI caused by *S. aureus*.

In this study, we cocultured MDSCs and T cells to examine how GMI influences
the suppression of T cell proliferation by MDSCs. We found that when coculturing T
cells with MDSCs, a 30% T proliferation was observed; a 20% proliferation was observed
when T cells were cocultured with MDSCs from BMCs treated with *S. aureus* biofilms
(Figure 2). This finding is consistent with results that *S. aureus* biofilms stimulate MDSC
expansion to inhibit T cell proliferation [20]. This study also showed that GMI promoted
T cell proliferation that is suppressed by both types of MDSCs. At 2.5 µg/mL of GMI,
the suppression of T cell proliferation by MDSCs and the MDSCs from biofilm-treated
BMCs was reduced and a 60% proliferation was observed (Figure 2), showing that GMI
significantly reduced the suppression of Tc proliferation by MDSCs from biofilm-treated
BMCs. More importantly, Tc cells were more responsive to GMI treatment than TH and
Treg cells, showing that GMI specifically reduced the suppression of Tc proliferation by
MDSCs. The stimulation of T cell proliferation by GMI may be attributed to its ability
to promote the expression of IL-6 and TNF-α (Figure 1). GMI is an FIP with a sequence
and structure similar to Lingzhi 8 (LZ8) from *Ganoderma microsporum*. LZ-8 is known
to induce mouse splenocytes, human peripheral blood lymphocytes, PBMC, and T cell
proliferation and activation [22,24,42]. LZ-8 also upregulates the expression of IL-2, TNF-α,
IFN-γ, and IL-1β [43,44]. It is well known that IL-6, TNF-α, and IL-1, influence MDSC
expansion [40,45,46] and promote the T cell proliferation [35]. Meanwhile, the expression
of IL-6 reduces apoptosis of CD4 T cells [47], increases activated T cells migration [48],
and regulates Th1/Th2 balance toward Th2 differentiation [49]. Importantly, IL-6 promotes
differentiation of naïve CD8 T cell into a unique population of effector CD8+ T cells for
antagonizing the viral infection [50]. It is also known that TNF-α promotes T cell activation
and proliferation [51]. The increases in TNF-α and IL-6 levels may explain how GMI
promotes proliferation Tc cells.

Finally, we examined how the administration of GMI benefits the treatment of PJI in
an *S. aureus*-induced PJI mouse model. We found that GMI treatment reduced osteolytic
destructions (Figure 6). We also found that MDSC expansion was reduced in GMI treatment
groups but increased IL-6 and TNF-α expression, which were consistent with the in vitro
results (Figures 1–4). It is known that *S. aureus* promotes local MDSC accumulation
in the infected regions [37–40]. To demonstrate how GMI affected the accumulation of
MDSC in prosthesis, we injected mice MDSCs and observed by fluorescence molecular
tomography (FMT), the aggregation of MDSC in the lesion reduced significantly during
the studying period, showing that GMI reduces accumulation of MDSCs at the injection sites. This study demonstrates that GMI is an attractive compound potentially beneficial to the treatment of PJI.

Author Contributions: Conceived and designed the experiments: K.-T.P., T.-Y.H., P.-J.C. Performed the experiments: K.-T.P., J.-L.C., L.-T.K., C.-W.L. Analyzed and interpreted the data: K.-T.P., P.-A.Y., W.-H.H. Contributed reagents/materials/analysis tools: T.-Y.H., C.-W.L. Contributed to the writing of the manuscript: K.-T.P., T.-Y.H., P.-J.C., J.-L.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Chang Gung Medical Research Program Foundation (grants CMRPG6J0231-0232 and CMRPG6H0402 from the Chang Gung Memorial Hospital Taiwan), and the Ministry of Science and Technology (R.O.C.) (grants NMRRPG6K6011-6012) [MOST 109-2314-B-182A-024-MY3].

Institutional Review Board Statement: The studies were approved by the Institutional Animal Care and Use Committee of the Chang Gung Memorial Hospital (IACUC permit number: 2019122309).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Pei-Chun Chen for the excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ricciardi, B.F.; Muthukrishnan, G.; Masters, E.; Ninomiya, M.; Lee, C.C.; Schwarz, E.M. Staphylococcus aureus Evasion of Host Immunity in the Setting of Prosthetic Joint Infection: Biofilm and Beyond. Curr. Rev. Musculoskelet. Med. 2018, 11, 389–400. [CrossRef] [PubMed]
2. Gbejuade, H.O.; Lovering, A.M.; Webb, J.C. The role of microbial biofilms in prosthetic joint infections. Acta Orthop. 2015, 86, 147–158. [CrossRef]
3. Gallo, J.; Kolar, M.; Novotny, R.; Rihakova, P.; Ticha, V. Pathogenesis of prosthesis-related infection. Biomed. Pap. 2003, 147, 27–35. [CrossRef]
4. Rao, N.; Ziran, B.H.; Lipsky, B.A. Treating osteomyelitis: Antibiotics and surgery. Plast. Reconstr. Surg. 2011, 127 (Suppl. S1), S177–S187. [CrossRef]
5. Fagotti, L.; Tatka, J.; Salles, M.J.C.; Queiroz, M.C. Risk Factors and Treatment Options for Failure of a Two-Stage Exchange. Curr. Rev. Musculoskelet. Med. 2018, 11, 420–427. [CrossRef]
6. Vilchez, F.; Martinez-Pastor, J.C.; Garcia-Ramiro, S.; Bori, G.; Macule, F.; Sierra, J.; Font, L.; Mensa, J.; Soriano, A. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin. Microbiol. Infect. 2011, 17, 439–444. [CrossRef] [PubMed]
7. Bryan, A.J.; Abdel, M.P.; Sanders, T.L.; Fitzgerald, S.F.; Hanssen, A.D.; Berry, D.J. Irrigation and Debridement with Component Retention for Acute Infection After Hip Arthroplasty: Improved Results with Contemporary Management. J. Bone Jt. Surg. Am. 2017, 99, 2011–2018. [CrossRef] [PubMed]
8. Nodzo, S.R.; Boyle, K.K.; Spiro, S.; Nocon, A.A.; Miller, A.O.; Westrich, G.H. Success rates, characteristics, and costs of articulating antibiotic spacers for total knee periprosthetic joint infection. Knee 2017, 24, 1175–1181. [CrossRef] [PubMed]
9. Kurtz, S.M.; Lau, E.; Watson, H.; Schmier, J.K.; Parvizi, J. Economic burden of periprosthetic joint infection in the United States. J. Arthroplast. 2012, 27 (Suppl. S8), 61.e1–65.e1. [CrossRef] [PubMed]
10. Peel, T.N.; Dowsey, M.M.; Buisin, K.L.; Liew, D.; Cheong, P.F. Cost analysis of debridement and retention for management of prosthetic joint infection. Clin. Microbiol. Infect. 2013, 19, 181–186. [CrossRef]
11. Darbani, R.; Farshadfar, C.; Tavana, S.; Saljoughi, H.; Zonouri, S.S.; Branch, S.; Zonouri, S.S. Identification of DNA gyrase Subunit A Mutations Associated with Ciprofloxacin Resistance in Staphylococcus aureus Isolated from Nasal Infection in Kurdistan, Iran. J. Mol. Biol. Res. 2017, 7, 186–193. [CrossRef]
12. Yilmaz, E.S.; Aslantas, O. Antimicrobial resistance and underlying mechanisms in Staphylococcus aureus isolates. Asian Pac. J. Trop. Med. 2017, 10, 1059–1064. [CrossRef] [PubMed]
13. Foster, T.J. Antibiotic resistance in Staphylococcus aureus: Current status and future prospects. FEMS Microbiol. Rev. 2017, 41, 430–449. [CrossRef] [PubMed]
14. Drago, L.; De Vecchi, E.; Nicola, L.; Gismondo, M.R. In vitro evaluation of antibiotics’ combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect. Dis. 2007, 7, 111. [CrossRef] [PubMed]
15. Grundmann, H.; Aires-de-Sousa, M.; Boyce, J.; Tiemersma, E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368, 874–885. [CrossRef]
16. Hiramatsu, K.; Katayama, Y.; Yuzawa, H.; Itô, T. Molecular genetics of meticillin-resistant *Staphylococcus aureus*. *Int. J. Med. Microbiol.* 2002, 292, 67–74. [CrossRef]

17. Ciofu, O.; Rojo-Moliner, E.; Macia, M.D.; Oliver, A. Antibiotic treatment of biofilm infections. *APMIS* 2017, 125, 304–319. [CrossRef] [PubMed]

18. Flemming, H.C.; Wingender, J. The biofilm matrix. *Nat. Rev. Microbiol.* 2010, 8, 623–633. [CrossRef]

19. Medina, E.; Hartl, D. Myeloid-Derived Suppressor Cells in Infection: A General Overview. *J. Innate Immun.* 2018, 10, 407–413. [CrossRef]

20. Peng, K.T.; Hsieh, C.C.; Huang, T.Y.; Chen, P.C.; Shih, H.N.; Lee, M.S.; Chang, P.J. *Staphylococcus aureus* biofilm elicits the expansion, activation and polarization of myeloid-derived suppressor cells in vivo and in vitro. *PLoS ONE* 2012, 7, e0183271. [CrossRef] [PubMed]

21. Labrecque, J.; Charlebois, S. Functional foods: An empirical study on perceived health benefits in relation to pre-purchase intentions. *Nutr. Food Sci.* 2011, 41, 308–318. [CrossRef]

22. Zhao, S.; Gao, Q.; Rong, C.; Wang, S.; Zhao, Z.; Liu, Y.; Xu, J. Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products. *J. Fungi* 2020, 6, 269. [CrossRef]

23. Lin, C.H.; Hsiao, Y.M.; Ou, C.C.; Lin, Y.W.; Chiu, Y.L.; Lue, K.H.; Chang, J.G.; Ko, J.L. *GMI*, a Ganoderma immunomodulatory protein, inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. *Int. J. Nanomed.* 2012, 7, 1287–1300. [CrossRef] [PubMed]

24. Liu, Y.; Bastiaan-Net, S.; Wichers, H.J. Current Understanding of the Structure and Function of Fungal Immunomodulatory Proteins. *Front. Nutr.* 2020, 7, 132. [CrossRef]

25. Chang, Y.C.; Chow, Y.H.; Sun, H.L.; Liu, Y.F.; Lee, Y.T.; Lue, K.H.; Ko, J.L. Alleviation of respiratory syncytial virus replication and inflammation by fungal immunomodulatory protein FIP-lve from *Fusarium velutipes*. *Antivir. Res.* 2014, 110, 124–131. [CrossRef]

26. Chen, W.Y.; Chang, C.Y.; Li, J.R.; Wang, J.D.; Wu, C.C.; Kuan, Y.H.; Liao, S.L.; Wang, W.Y.; Chen, C.J. Anti-inflammatory and anti-oxidative agent for treating periprosthetic joint infections. *Int. J. Nanomed.* 2019, 14, 3678. [CrossRef] [PubMed]

27. Wu, M.-y.; Hsu, M.-F.; Huang, C.-S.; Fu, H.-y.; Wang, A.; Hsue, R.-S.; Huang, C.-T.; Yang, C.-S. A 2.0 Å Structure of the Fungal Immunomodulatory Protein GMI from *Ganoderma microsporum*. In Proceedings of the 2nd Asia-Oceania Forum for Synchrotron Radiation Research, Hsinchu, Taiwan, 2–3 November 2007.

28. Hsin, I.L.; Sheu, G.T.; Jan, M.S.; Sun, H.L.; Wu, T.C.; Chiu, L.Y.; Lue, K.H.; Ko, J.L. Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from *Ganoderma microsporum*. *Br. J. Pharm.* 2012, 167, 1287–1300. [CrossRef] [PubMed]

29. Hsin, I.L.; Ou, C.C.; Wu, T.C.; Jan, M.S.; Wu, M.F.; Chiu, L.Y.; Lue, K.H.; Ko, J.L. GMI, an immunomodulatory protein from *Ganoderma microsporum*, induces autophagy in non-small cell lung cancer cells. *Autophagy* 2011, 7, 873–882. [CrossRef] [PubMed]

30. Lin, C.H.; Hsiao, Y.M.; Ou, C.C.; Lin, Y.W.; Chiu, Y.L.; Lue, K.H.; Chang, J.G.; Ko, J.L. *GMI*, a Ganoderma immunomodulatory protein, down-regulates tumor necrosis factor alpha-induced expression of matrix metalloproteinase 9 via NF-κB pathway in human alveolar epithelial A549 cells. *J. Agric. Food Chem.* 2010, 58, 12014–12021. [CrossRef] [PubMed]

31. Lin, C.-H.; Sheu, G.-T.; Lin, Y.-W.; Yeh, C.-S.; Huang, Y.-H.; Lai, Y.-C.; Chang, J.-G.; Ko, J.-L. A new immunomodulatory protein from *Ganoderma microsporum* inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. *Proc. Biochem.* 2010, 45, 1537–1542. [CrossRef]

32. Eruslanov, E.; Kusmartsev, S. Identification of ROS using oxidized DCFDA and flow-cytometry. *Methods Mol. Biol.* 2009, 594, 57–72. [PubMed]

33. Tankersley, A.; Frank, M.B.; Bebak, M.; Brennan, R. Early effects of *Staphylococcus aureus* biofilm secreted products on inflammatory responses of human epithelial keratinocytes. *J. Inflamm.* 2011, 8, 53–62. [CrossRef] [PubMed]

34. Ohl, K.; Tenbrock, K. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression. *Front. Immunol.* 2018, 9, 2499. [CrossRef] [PubMed]

35. Dienz, O.; Rincon, M. The effects of IL-6 on CD4 T cell responses. *Clin. Immunol.* 2009, 130, 27–33. [CrossRef]

36. Peng, K.T.; Chiang, Y.C.; Huang, T.Y.; Chen, P.C.; Chang, P.J.; Lee, C.W. Curcumin nanoparticles are a promising anti-bacterial and anti-inflammatory agent for treating periprosthetic joint infections. *Int. J. Nanomed.* 2019, 14, 469–481. [CrossRef] [PubMed]

37. Skabytska, Y.; Wolbing, F.; Gunther, C.; Koberle, M.; Kaesler, S.; Chen, K.M.; Guenova, E.; Demircio glu, D.; Kempf, W.E.; Volz, T.; et al. Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. *Immunity* 2014, 41, 762–775. [CrossRef]

38. Heim, C.E.; Vidlak, D.; Kielian, T. Interleukin-10 production by myeloid-derived suppressor cells contributes to bacterial persistence during *Staphylococcus aureus* orthopedic biofilm infection. *J. Leukoc. Biol.* 2015, 98, 1003–1013. [CrossRef] [PubMed]

39. Heim, C.E.; Vidlak, D.; Scherr, T.D.; Hartman, C.W.; Garvin, K.L.; Kielian, T. IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during *Staphylococcus aureus* orthopedic implant infection. *J. Immunol.* 2015, 194, 3861–3872. [CrossRef] [PubMed]

40. Dorhoi, A.; Du Plessis, N. Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. *Front. Immunol.* 2017, 8, 1895. [CrossRef] [PubMed]

41. Singh, S.; Singh, S.K.; Chowdhury, I.; Singh, R. Understanding the Mechanism of Bacterial Biofilms Resistance to Antimicrobial Agents. *Open Microbiol. J.* 2017, 11, 53–62. [CrossRef] [PubMed]
42. Lin, T.Y.; Hua, W.J.; Yeh, H.; Tseng, A.J. Functional proteomic analysis reveals that fungal immunomodulatory protein reduced expressions of heat shock proteins correlates to apoptosis in lung cancer cells. *Phytomedicine* 2021, 80, 153884. [CrossRef] [PubMed]
43. Haak-Frendscho, M.; Kino, K.; Sone, T.; Jardieu, P. Ling Zhi-8: A novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. *Cell Immunol.* 1993, 150, 101–113. [CrossRef]
44. Hsu, H.Y.; Hua, K.F.; Wu, W.C.; Hsu, J.; Weng, S.T.; Lin, T.L.; Liu, C.Y.; Hseu, R.S.; Huang, C.T. Reishi immuno-modulation protein induces interleukin-2 expression via protein kinase-dependent signaling pathways within human T cells. *J. Cell Physiol.* 2008, 215, 15–26. [CrossRef] [PubMed]
45. Fang, Z.; Li, J.; Yu, X.; Zhang, D.; Ren, G.; Shi, B.; Wang, C.; Kosinska, A.D.; Wang, S.; Zhou, X.; et al. Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. *J. Immunol.* 2015, 195, 4873–4883. [CrossRef]
46. Garg, A.; Spector, S.A. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. *J. Infect. Dis.* 2014, 209, 441–451. [CrossRef]
47. Rochman, I.; Paul, W.E.; Ben-Sasson, S.Z. IL-6 increases primed cell expansion and survival. *J. Immunol* 2005, 174, 4761–4767. [CrossRef] [PubMed]
48. Weissenbach, M.; Clahsen, T.; Weber, C.; Spitzer, D.; Wirth, D.; Vestweber, D.; Heinrich, P.C.; Schaper, F. Interleukin-6 is a direct mediator of T cell migration. *Eur. J. Immunol.* 2004, 34, 2895–2906. [CrossRef]
49. Diehl, S.; Rincon, M. The two faces of IL-6 on Th1/Th2 differentiation. *Mol. Immunol.* 2002, 39, 531–536. [CrossRef]
50. Neumann, J.; Prezzemolo, T.; Vanderbeke, L.; Roca, C.P.; Gerbaux, M.; Janssens, S.; Willemsen, M.; Burton, O.; van Mol, P.; van Herck, Y.; et al. Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. *Clin. Transl. Immunol.* 2020, 9, e1204. [CrossRef]
51. Mehta, A.K.; Gracias, D.T.; Croft, M. TNF activity and T cells. *Cytokine* 2018, 101, 14–18. [CrossRef]